Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results